What will pharma's share buyback shopping spree mean for M&A?
A handful of cash-rich pharma companies have announced billions of dollars in share buybacks in recent months, raising questions about their interest in transformative dealmaking this year. Eli Lilly,...
View ArticleSummer buys Caraway, as startups keep deals in the VC family
Last week, Summer Health, a provider of urgent care for kids, said it acquired Caraway Health, which offers virtual care tailored to Gen Z. The deal is another tying together two startups with the same...
View ArticleFDA puts two Chinese API makers on import alert after failed inspections
Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert over issues with their quality control and testing methods. The import alerts...
View ArticleBiohaven gets FDA priority review for neuro disease drug after refuse-to-file
Biohaven's experimental drug troriluzole for the rare, neurodegenerative disease spinocerebellar ataxia will get a priority review from the FDA, after the company presented additional real-world data....
View ArticleTravere plans to seek expanded label for kidney drug
Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known as focal segmental glomerulosclerosis, or FSGS, using a secondary endpoint...
View ArticleSpringWorks lands FDA approval for nerve tumor treatment
SpringWorks Therapeutics, a biotech potentially on the verge of being acquired, won its second FDA approval. The agency on Tuesday gave the green light to Gomekli, a treatment for adults and ...
View ArticleNew CMO Dietmar Berger highlights Gilead’s ‘unique situation’ and its HIV...
Dietmar Berger said Gilead is in a “unique situation” as he assumes the role of chief medical officer, touting a “well-diversified" pipeline, potential launches and an eight-year stretch of no major...
View ArticleBiogen gets $250M in Royalty Pharma deal for lupus program
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday. The two have agreed on a deal for litifilimab, an anti-BDCA2 drug...
View ArticleExclusive: Longevity startup targets renegade proteins linked to diabetes and...
The human genome is chock-full of middle managers. Roughly 2,000 proteins, accounting for one-tenth of our genes, control how the rest of our genes are turned on or off. Normally these ...
View ArticleAfter passing on M&A offers, Abcuro raises $200M in bid to become commercial...
After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a $60 million to $80 million fundraise. That...
View ArticleCerula Care raises $3.7M to support cancer patients’ mental health
Cerula Care has raised $3.7 million in seed funding to help patients better fight cancer by checking in on them, supporting their mental health and helping with practical needs such as nudges to take...
View ArticleBiogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet
Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics: Biogen appears to back away from dealmaking projections: The...
View ArticleAbbVie pens another T cell engager deal, this time with Xilio
AbbVie and Xilio Therapeutics are partnering to make “masked” T cell engagers, which they hope will be safer than currently available options. Xilio said Wednesday the collaboration would develop new...
View ArticleAnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year. Anaptys’ program, known as rosnilimab, hit its...
View ArticlePfizer wins approval in new indication for blood cancer drug Adcetris
Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in combination with two other medications, to treat relapsed or refractory large B cell...
View ArticleWhat CVS is doing about high medical costs
CVS Health ended 2024 as it started, with high medical costs in the company’s insurance business chipping away at its bottom line. The healthcare giant late last year tapped new CEO David Joyner to...
View ArticleKaiser Permanente calls on FDA and Congress to firm up accelerated approval...
While FDA is implementing new accelerated approval reforms, Kaiser Permanente says the reforms do not go far enough. The health system, which owns an insurer, said the agency needs to work with...
View ArticleNIH’s funding cut plan poses challenges for researchers despite court halt
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it. A federal judge this week
View ArticleNovo's weight loss drug helps curb some drinking habits, small study shows
New research from the University of North Carolina-Chapel Hill found that Novo Nordisk’s weight loss drug may help people curb their alcohol consumption. Results from the small Phase 2 study
View ArticleEx-DeepMind scientist launches AI biotech Latent Labs with $50M
Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of proteins. Now, Kohl is venturing out on his...
View Article